Proposal for Change in the Board of Directors of Nanologica AB (publ)

Alexandra Blomberg Montgomery is proposed to be elected as a new member of the board of directors of Nanologica at the Extraordinary General Meeting on September 23, 2024.

Alexandra Blomberg Montgomery has extensive experience in advising companies operating in several sectors through her years as a partner at KREAB, where she has also held several senior positions, including in international business development. Furthermore, Alexandra has experience of medical research from a board perspective, for example as a board member of the Ragnar Söderberg Foundation. Alexandra works primarily with investments in both listed and unlisted environments and thus brings the investor perspective to the board.

Alexandra Blomberg Montgomery owns shares privately in Nanologica AB and in addition represents the ownership in several foundations, including the Andre Oscar and Anna Wallenberg Foundation, a total of about 5 percent.

The Extraordinary General Meeting of Nanologica AB (publ) will be held on Thursday, September 23, 2024, at 12:00 noon at Redeye AB's premises at Mäster Samuelsgatan 42, 10th floor, in Stockholm. Notice and meeting documents are available on the company’s website.

About Nanologica AB (publ)
Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica's share (NICA) is listed for trading on Nasdaq Stockholm Main Market. For further information, please visit www.nanologica.com.

About us

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.